Russia claims new Ebola vaccine may protect against Bundibugyo strain

Russia has announced that its scientists have developed a candidate vaccine that may offer protection against the Bundibugyo strain of the Ebola virus, which is currently causing outbreaks in the Democratic Republic of Congo (DRC) and Uganda. The announcement was made by Russian Health Minister Mikhail Murashko and communicated via the Russian Embassy in South Africa on social media platform X. The Bundibugyo strain is a less common but highly dangerous variant of Ebola, and crucially, there are currently no fully approved vaccines or specific treatments designed for it, unlike the more common Zaire ebolavirus strain. This lack of specific medical countermeasures highlights the urgency and significance of Russia's claim. The World Health Organization (WHO) has declared the ongoing outbreaks in the DRC and Uganda a Public Health Emergency of International Concern (PHEIC), underscoring the severity of the situation. The Africa Centres for Disease Control and Prevention (Africa CDC) has also classified it as a Public Health Emergency of Continental Security (PHECS). [3, 5, 8, 11, 15, 20, 21] Scientists at Russia's Gamaleya Research Centre, including its Scientific Director Alexander Gintsburg, have stated that their existing Ebola vaccines likely offer protection against the Bundibugyo strain due to a genetic similarity of about 60-70%. They proposed vaccinating health workers in outbreak areas based on this genetic similarity. [6, 11] However, this claim has been met with caution from the international scientific community. Experts emphasize that while the genetic similarity is a promising indicator, it is not definitive proof of efficacy. Large-scale clinical trials with transparent data are considered essential before any vaccine can be incorporated into the global Ebola response. [5, 6] The Gamaleya Center has reportedly developed a specific vaccine candidate against the Bundibugyo strain, which is currently in preclinical trials, with testing on monkeys underway. [12] It is important to note that Russia has a history of developing Ebola vaccines. The Gamaleya Center registered two vector-based Ebola vaccines in 2015 and another in 2020, which have been approved by the Russian Health Ministry. Approximately 2,000 people in Guinea received these vaccines in 2017-18. [16, 17, 22] However, these vaccines have not been licensed by major international regulatory bodies like the WHO, European Medicines Agency (EMA), or the US Food and Drug Administration (FDA). [6] The current outbreak in the DRC has been particularly severe, with the situation expanding to multiple health zones across several provinces. As of early September 2026, the DRC reported over 6,700 confirmed cases and more than 3,200 deaths. Uganda has also reported cases, though its outbreak was declared over in late August 2026. [9, 15, 20, 21] In response to the outbreak, global health agencies have been working on various fronts. Expert advisory groups have prioritized two candidate vaccines and three therapeutics for clinical trials, with significant funding committed to accelerate research. [6] The development of vaccines specifically for the Bundibugyo strain is ongoing, with candidates from institutions like the International AIDS Vaccine Initiative (IAVI) and Oxford University (in collaboration with the Serum Institute of India) also being fast-tracked. [6, 10] While Russia's claim offers a potential new avenue in the fight against Ebola, the scientific community's emphasis on rigorous testing and validation remains paramount. The situation highlights the ongoing global effort to combat infectious diseases and the importance of international collaboration and transparency in vaccine development and deployment. The article's source, drugscontrol.org, is not a widely recognized or reputable news outlet. The claims made in the original article are largely corroborated by other news sources, but the original source itself lacks credibility. The timing of the claims is also somewhat conflated, with some reports dating back to 2016 and others to mid-2026, making it difficult to pinpoint the exact timeline of the *new* vaccine announcement. The Bundibugyo outbreak has been ongoing since May 2026. [15, 21]

Frequently Asked Questions

Read Full Story on Quick Digest